Cargando…

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

SIMPLE SUMMARY: Malignant pleural mesothelioma (MPM) is characterized by the lack of effective long-term treatments and highly prevalent drug resistance. The paucity of potential therapeutic targets has led to dismal prognosis. We have examined the functional role of the signal transducer and activa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lapidot, Moshe, Case, Abigail E., Larios, Dalia, Gandler, Helen I., Meng, Chengcheng, Tošić, Isidora, Weisberg, Ellen L., Poitras, Michael J., Gokhale, Prafulla C., Paweletz, Cloud P., Podar, Klaus, Salgia, Ravi, Saladi, Srinivas V., Griffin, James D., Frank, David A., Bueno, Raphael, Sattler, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792575/ https://www.ncbi.nlm.nih.gov/pubmed/33374980 http://dx.doi.org/10.3390/cancers13010007

Ejemplares similares

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2021)

Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2022)

Malignant Pleural Mesothelioma (MPM) Presenting as Hydropneumothorax
por: Kuramochi, Masami, et al.
Publicado: (2023)

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
por: Pagano, Maria, et al.
Publicado: (2020)

Pleurectomy decortication is the preferred surgical procedure in pleural mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2023)

Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
por: Wright, Casey M., et al.
Publicado: (2013)

KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
por: Lorenzini, Eugenia, et al.
Publicado: (2022)

The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM)
por: Yuen, Man Lee, et al.
Publicado: (2021)

Genomic and Transcriptomic Analyses of Malignant Pleural Mesothelioma (MPM) Samples Reveal Crucial Insights for Preclinical Testing
por: Laure, Alexander, et al.
Publicado: (2023)

Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients
por: Cedres, Susana, et al.
Publicado: (2023)

MA04.07 Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection
por: Cedres, S., et al.
Publicado: (2021)

A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma
por: Li, Wei, et al.
Publicado: (2023)

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
por: Cedrés, Susana, et al.
Publicado: (2015)

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)
por: Mendoza, Tito R., et al.
Publicado: (2019)

The Use of Immunohistochemistry, Fluorescence in situ Hybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
por: Rozitis, Eric, et al.
Publicado: (2020)

Heparanase inhibitors restrain mesothelioma
por: Lapidot, Moshe, et al.
Publicado: (2018)

In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM)
por: Singh, Anand S., et al.
Publicado: (2018)

Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures
por: Sarun, Kadir Harun, et al.
Publicado: (2018)

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)
por: Hassan, Raffit, et al.
Publicado: (2015)

Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2
por: Kuwata, Taiji, et al.
Publicado: (2020)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022)

The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study
por: Zauderer, Marjorie G, et al.
Publicado: (2021)

Simplified approach to ICU severity scoring with MPM and EUROSCORE
por: Reeves, JH, et al.
Publicado: (2010)

Preliminary update of the Mortality Probability Model (MPM0)
por: Higgins, T, et al.
Publicado: (2005)

A Novel Panel of Serum Biomarkers for MPM Diagnosis
por: Bonotti, A., et al.
Publicado: (2017)

Prognostic and predictive role of [(18)F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
por: Zucali, Paolo Andrea, et al.
Publicado: (2017)

Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia
por: Weisberg, Ellen, et al.
Publicado: (2020)

Pericardial Effusion due to Primary Malignant Pericardial Mesothelioma: A Common Finding but an Uncommon Cause
por: Istomin, Valery, et al.
Publicado: (2016)

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming
por: Bhanot, Haymanti, et al.
Publicado: (2017)

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
por: Weisberg, Ellen, et al.
Publicado: (2020)

Cell-Free DNA in Oncology: Gearing up for Clinic
por: Ulrich, Bryan C., et al.
Publicado: (2018)

MTA1 promotes metastasis of MPM via suppression of E-cadherin
por: Xu, Caihua, et al.
Publicado: (2015)

Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM)
por: Ferguson, Robert, et al.
Publicado: (2019)

Leaf Plasmodesmata Respond Differently to TMV, ToBRFV and TYLCV Infection
por: Kutsher, Yaarit, et al.
Publicado: (2021)

EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma
por: Tan, Yi-Hung Carol, et al.
Publicado: (2019)

STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications
por: Tošić, Isidora, et al.
Publicado: (2021)

At least two kinases phosphorylate the MPM-2 epitope during Xenopus oocyte maturation
Publicado: (1993)

Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications
por: Tolani, Bhairavi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gnna14b81n3af84nu6qrt59liq